XFOR (X4 Pharmaceuticals) Ending Cash Position: $217.49 Mil (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
24 GF Score
Price $4.12
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Ending Cash Position?

X4 Pharmaceuticals XFOR +1.10% 24 Ending Cash Position is $217.49 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 24/100. The stock has 7 warning signs investors should review.

X4 Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $217.49 Mil.

X4 Pharmaceuticals's quarterly Ending Cash Position increased from Sep. 2025 ($70.44 Mil) to Dec. 2025 ($217.85 Mil) but then declined from Dec. 2025 ($217.85 Mil) to Mar. 2026 ($217.49 Mil).

X4 Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($100.25 Mil) to Dec. 2024 ($56.48 Mil) but then increased from Dec. 2024 ($56.48 Mil) to Dec. 2025 ($217.85 Mil).

X4 Pharmaceuticals Ending Cash Position Related Terms

X4 Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Ending Cash Position Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.11 123.03 100.25 56.48 217.85

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.04 40.02 70.44 217.85 217.49
XFOR
24GF Score
X4 Pharmaceuticals Inc XFOR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

X4 Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=56.475+161.377
=217.85

X4 Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=217.852+-0.365
=217.49

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $217.49 Mil mean?
X4 Pharmaceuticals (XFOR) has a Ending Cash Position of $217.49 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Ending Cash Position too high?
X4 Pharmaceuticals' current Ending Cash Position is $217.49 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Ending Cash Position compare to CMPX and LRMR?
X4 Pharmaceuticals' Ending Cash Position of $217.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Ending Cash Position is $217.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Ending Cash Position of $217.49 Mil. The current Ending Cash Position is $217.49 Mil. X4 Pharmaceuticals' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Ending Cash Position is $217.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
24GF Score

Get the complete analysis for XFOR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price